-
N3-kethoxal Workflows for RNA and DNA Mapping
2026-09-05
N3-kethoxal converts exposed guanines into click-ready landmarks for RNA structure probing, accessible-DNA mapping, and nucleic acid interaction studies. This practical guide connects assay design with the emerging biology of NET-associated ssDNA and thrombin while emphasizing controls, optimization, and interpretation limits.
-
SIA-cIgG, PTPN13, and Cisplatin in HNSCC
2026-09-05
A 2026 study identifies the SIA-cIgG/PTPN13 axis as a regulator of tumor stemness and chemotherapy resistance in head and neck squamous cell carcinoma. Its combination of anti-SIA-cIgG treatment, standard chemotherapy, xenograft models, and patient-derived organoids provides a mechanistic and translational framework for improving CDDP response.
-
GKT137831: Dual Nox1/Nox4 Inhibitor Workflow
2026-09-04
Build more interpretable oxidative-stress experiments with GKT137831, a dual NADPH oxidase Nox1/Nox4 inhibitor for vascular, fibrosis, and metabolic disease models. This guide combines dose planning, ROS and membrane-integrity readouts, translational applications, and troubleshooting while placing recent ferroptosis findings in the correct hypothesis-generating context.
-
B3465: α2-Adrenergic Receptor Agonist
2026-09-04
Explore how 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine can support rigorous α2-adrenergic receptor signaling studies. This article focuses on assay design, immune-versus-tumor mechanisms, formulation constraints, and practical interpretation of osteosarcoma recurrence research.
-
Dacarbazine Assays: From DNA Damage to Cell Killing
2026-09-03
Turn Dacarbazine exposure into a more informative cancer assay by separating growth inhibition from true cell killing. This workflow combines time-resolved viability measurements, careful formulation, and model-specific interpretation for melanoma, lymphoma, and sarcoma research.
-
Y-27632 ROCK Inhibitor for Organoid Workflows
2026-09-02
Y-27632 provides a reversible, selective way to tune ROCK-dependent cytoskeletal behavior during cell recovery, organoid establishment, and imaging assays. This practical guide connects patient-derived colorectal organoid workflows with dose selection, washout controls, and troubleshooting strategies for more reproducible cancer biology research.
-
TIA1–CLSTN1 Splicing Axis in Breast Cancer
2026-09-02
A 2026 Oncogene study identifies a DAPK3–TIA1–CLSTN1 regulatory axis in which loss or phosphorylation-mediated inhibition of TIA1 increases CLSTN1 exon 11 inclusion and promotes breast cancer metastasis. Splice-switching antisense oligonucleotides reversed this event and reduced migration, providing a mechanistic and therapeutic framework for targeting pro-metastatic RNA splicing.
-
APOBEC3, IL-1α, and Squamous Bladder Cancer
2026-09-01
The reference study identifies mouse Apobec3 and human APOBEC3A as drivers of squamous trans-differentiation in urothelial carcinoma, linking this phenotype to IL-1α and downstream AP-1 signaling. Its combination of genetically engineered mice, bulk RNA sequencing, single-cell transcriptomics, and spatial profiling provides a framework for studying tumor-state transitions and for evaluating pathway-specific interventions.
-
NBC19: NLRP3 Inflammasome Inhibitor Workflow
2026-09-01
NBC19 provides a nanomolar tool for separating NLRP3-dependent IL-1β signaling from broader macrophage inflammatory programs. This workflow combines stimulus-matched THP-1 assays with lactate–HMGB1 measurements to support more rigorous inflammation research and troubleshooting.
-
Honeybee Smoothened Signaling and Olfaction
2026-08-31
Guo and colleagues characterized Smoothened (Smo) in Apis mellifera and connected antenna-enriched Smo expression with olfactory receptor regulation, electrophysiological responses, and odor-guided behavior. The study provides a useful pharmacological framework for insect sensory biology while showing why drug perturbation should be interpreted cautiously as evidence of pathway involvement rather than direct molecular causality.
-
Entinostat (MS-275) Cancer Assay Workflow
2026-08-31
Entinostat (MS-275) supports selective class I HDAC research while helping investigators distinguish growth arrest from true cancer-cell killing. This workflow combines target-engagement assays, longitudinal viability measurements, and death-specific endpoints for more interpretable oncology data.
-
AO/PI Staining Solution for Live/Dead Counting
2026-08-30
AO/PI Staining Solution combines two fluorescent DNA dyes to distinguish membrane-intact and membrane-compromised cells. The dual-color readout supports fluorescence-based cell counting and reduces interference from debris and residual red blood cells when the sample and instrument are properly validated.
-
Mtb–BMX Signaling Suppresses Lysosomal Acidification
2026-08-29
The reference study identifies a host–pathogen mechanism in which Mycobacterium tuberculosis uses the secreted protein Chp2/Rv1184 to promote BMX-dependent phosphorylation of ATP6V1E1, weakening V-ATPase assembly and lysosomal acidification. By linking a bacterial effector to host kinase signaling and intracellular bacterial growth, the work provides a mechanistic basis for investigating lysosomal acidification as a host-directed therapeutic strategy.
-
MTT Assay Workflow for Cell Viability Studies
2026-08-28
Build a reproducible MTT workflow for measuring cell proliferation, metabolic activity, and treatment-related cytotoxicity in vitro. The article translates an X-ray-triggered doxorubicin nanomicelle study into practical assay controls, protocol parameters, and troubleshooting decisions for radiation–drug experiments.
-
Affordable GRO-seq for Nascent RNA in Bread Wheat
2026-08-28
Chen and colleagues introduce a cost-conscious GRO-seq protocol that removes ribosomal RNA after nuclear RNA isolation and before nascent-RNA immunoprecipitation. Applied to allohexaploid bread wheat, the workflow substantially increased the proportion of usable sequencing data while enabling enhancer-transcription profiling in a complex genome.